Buy-rated reports

573 tickers rated Buy
Ranks this page's recent reports by score.
Sphere Entertainment Co.
SPHR·Communication Services
A ★★★★Buy
Current$168.00
Target$215.33
Return+28.2%
Aug 17, 2026

Sphere Entertainment is the undisputed, highly scalable monopoly of ultra-immersive live entertainment, poised for massive margin expansion via a capital-light global franchise model, though investors must tolerate the structural drag of its legacy regional sports networks.

Score
86
Choice Hotels International, Inc.
CHH·Consumer Discretionary
A ★★★★Buy
Current$104.44
Target$135.00
Return+29.3%
Aug 17, 2026

Choice Hotels is an elite, cash-generative lodging franchisor trading at a massive valuation discount to peers, offering explosive capital return potential as it completes its asset-light transition, though investors must navigate near-term leadership uncertainty and economy-segment weakness.

Score
94
Valvoline Inc.
VVV·Consumer Discretionary
A ★★★★Buy
Current$34.19
Target$39.82
Return+16.5%
Aug 17, 2026

Valvoline is the undisputed, highly scalable tollbooth of the non-discretionary automotive maintenance sector, trading at an absurdly low implied growth rate, though investors must remain vigilant regarding its elevated debt load and backend IT integration risks.

Score
85
Lemonade, Inc.
LMND·Financials
A ★★★★Buy
Current$52.64
Target$84.75
Return+61.0%
Aug 17, 2026

Lemonade's AI-driven platform is fundamentally reshaping personal lines insurance with hyper-growth scaling, improving loss ratios, and impending EBITDA profitability, though intense competition and macro catastrophe risks necessitate vigilant monitoring.

Score
85
Figure Technology Solutions, Inc.
FIGR·Financials
A ★★★★Buy
Current$31.43
Target$51.00
Return+62.3%
Aug 17, 2026

Figure is fundamentally rewiring the multi-trillion-dollar U.S. mortgage market with high-margin, capital-light blockchain infrastructure, though investors must vigilantly monitor net take rate compression and the regulatory vulnerabilities of tokenized securities.

Score
85
Valaris Limited
VAL·Energy
A ★★★★Buy
Current$85.62
Target$95.55
Return+11.6%
Aug 17, 2026

Valaris operates as an elite, fortress-balance-sheet tollbooth on the accelerating deepwater exploration cycle, trading at a severely discounted multiple due to merger arbitrage, though investors must continuously monitor the outcome of the DOJ antitrust review.

Score
87
BGC Group, Inc.
BGC·Financials
A ★★★★Buy
Current$11.20
Target$16.50
Return+47.3%
Aug 17, 2026

BGC is rapidly transforming from a traditional voice broker into a high-margin electronic trading powerhouse via its FMX platform, trading at a steep discount to exchange peers, though investors must monitor execution risks against entrenched monopolistic competitors like CME Group.

Score
91
Resideo Technologies, Inc.
REZI·Industrials
A ★★★★Buy
Current$20.46
Target$35.00
Return+71.1%
Aug 16, 2026

Resideo is a wildly profitable, pure-play building technology powerhouse trading at a severely distressed multiple due to post-spin leverage panic, though investors must vigilantly monitor management's execution of its aggressive debt-reduction mandate.

Score
90
Zeta Global Holdings Corp.
ZETA·Technology
A ★★★★Buy
Current$29.05
Target$39.93
Return+37.5%
Aug 16, 2026

Zeta's profitable, fast-growing AI infrastructure trades at a peer discount, but regulatory risks around proprietary data collection and consent remain headwinds.

Score
90
ESAB Corporation
ESAB·Industrials
A ★★★★Buy
Current$85.58
Target$108.93
Return+27.3%
Aug 16, 2026

ESAB is executing a masterful, high-margin transformation into an industrial software and inspection powerhouse, trading at a deeply misunderstood discount, though investors must tolerate near-term balance sheet leverage as the company digests its massive acquisition.

Score
86
Legence Corp.
LGN·Industrials
A ★★★★Buy
Current$66.38
Target$105.00
Return+58.2%
Aug 16, 2026

Legence is the premier, pure-play tollbooth for the secular data center and semiconductor reshoring supercycles, offering massive cash generation and a $5.67 billion backlog, though investors must navigate near-term margin mix dilution and heavy insider stock liquidations.

Score
85
Ascendis Pharma A/S
ASND·Healthcare
A ★★★★Buy
Current$255.46
Target$310.00
Return+21.4%
Aug 16, 2026

Ascendis Pharma's TransCon technology platform is rapidly scaling a highly profitable rare disease portfolio led by Yorvipath and Yuviwel, though investors must monitor ongoing BioMarin patent litigation and reliance on a single drug delivery mechanism.

Score
86